Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| B-D-Galactose SCHEMBL307801 | 1.00 | APP (0.68) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| D-Galactose SCHEMBL15391861 | 1.00 | APP (0.68) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| Beta-D-Glucose SCHEMBL383291 | 0.87 | SLC5A2 (0.49) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| B-D-Galactose SCHEMBL1712843 | 0.87 | SLC5A2 (0.49) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| D-Galactose SCHEMBL2370315 | 0.87 | SLC5A2 (0.49) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| Dextrose SCHEMBL5679244 | 0.87 | SLC5A2 (0.49) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| B-D-Galactose SCHEMBL8515088 | 0.87 | SLC5A2 (0.49) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| B-D-Galactose SCHEMBL307802 | 0.87 | SLC5A2 (0.49) | APPCYP1A2KDM4EALDH1A1MEN1 | |
| SCHEMBL8066 | 0.82 | APP (1.00) | APPCYP1A2MEN1KMT2APOLB | |
| Alcohol SCHEMBL6810203 | 0.81 | APP (0.86) | APPCYP1A2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197018-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | US | claimed |
| US-20240158776-A1 | NANOCAGED ENZYMES WITH ENHANCED CATALYTIC ACTIVITY AND INCREASED STABILITY | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2024-05-16 | — | — | US | disclosed |
| US-11903985-B2 | Gene therapies for lysosomal disorders | PREVAIL THERAPEUTICS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230310654-A1 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | PREVAIL THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11718854-B2 | Gene targets for improved enzyme production in fungi | BATTELLE MEMORIAL INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| EP-4192516-A2 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | Prevail Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11396522-B2 | Bis-acetal-based substrates for imaging exo-glycosidase activity | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-26 | — | — | US | disclosed |
| US-20220177887-A1 | RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| WO-2022035903-A2 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | PREVAIL THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210254077-A1 | GENE TARGETS FOR IMPROVED ENZYME PRODUCTION IN FUNGI | BATTELLE MEMORIAL INSTITUTE (US) | 2021-08-19 | — | — | US | disclosed |
| US-9802942-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170002013-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001976-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2017004408-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1.2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017004405-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20140113327-A1 | BIOCHEMICAL SENSOR FOR QUANTITATIVE SIMULTANEOUS MULTI-SPECIES BACTERIA DETECTION IN SITU | Environmental Technology Solutiions LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130260417-A1 | BIOCHEMICAL SENSOR FOR QUANTITATIVE SIMULTANEOUS MULTI-SPECIES BACTERIA DETECTION IN SITU | ENVIRONMENTAL TECHNOLOGY SOLUTIONS LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20100304378-A1 | Method for Detecting or Quantifying a Truncating Mutation | UNIVERSITE DE STRASBOURG (FR) | 2010-12-02 | — | — | US | disclosed |
| US-20100197018-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20080299666-A1 | Novel Peptide-Based Borono-Lectin (PBL) Sensors | UNIVERSITY OF SOUTH CAROLINA (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396522-B2 | Bis-acetal-based substrates for imaging exo-glycosidase activity | ENGASE, MAN2B2, GALE | APP 2595/4885CYP1A2 3948/4885KDM4E 1766/4885 |
| US-20080299666-A1 | Novel Peptide-Based Borono-Lectin (PBL) Sensors | LGALS3BP, LGALS1, BCAP31 | APP 1018/4885CYP1A2 4844/4885KDM4E 4626/4885 |
| US-20170001976-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GAA, GBA2 | APP 1951/4885CYP1A2 2508/4885KDM4E 3791/4885 |
| US-20170002013-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | APP 2322/4885CYP1A2 3203/4885KDM4E 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.